These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 21254232)

  • 1. Serum 25-hydroxyvitamin D level and acute-phase reaction following initial intravenous bisphosphonate.
    Srivastava T; Dai H; Haney CJ; Alon US
    J Bone Miner Res; 2011 Feb; 26(2):437-8. PubMed ID: 21254232
    [No Abstract]   [Full Text] [Related]  

  • 2. Atorvastatin may have no effect on acute phase reaction in children after intravenous bisphosphonate infusion.
    Srivastava T; Haney CJ; Alon US
    J Bone Miner Res; 2009 Feb; 24(2):334-7. PubMed ID: 18847329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum Markers of Bone Turnover and Angiogenesis in Patients With Bisphosphonate-Related Osteonecrosis of the Jaw After Discontinuation of Long-Term Intravenous Bisphosphonate Therapy.
    Thumbigere-Math V; Michalowicz BS; Hughes PJ; Basi DL; Tsai ML; Swenson KK; Rockwell L; Gopalakrishnan R
    J Oral Maxillofac Surg; 2016 Apr; 74(4):738-46. PubMed ID: 26501428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors associated with acute-phase response of bisphosphonate-naïve or pretreated women with osteoporosis receiving an intravenous first dose of zoledronate or ibandronate.
    Popp AW; Senn R; Curkovic I; Senn C; Buffat H; Popp PF; Lippuner K
    Osteoporos Int; 2017 Jun; 28(6):1995-2002. PubMed ID: 28299378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum 25-hydroxyvitamin D levels modulate the acute-phase response associated with the first nitrogen-containing bisphosphonate infusion.
    Bertoldo F; Pancheri S; Zenari S; Boldini S; Giovanazzi B; Zanatta M; Valenti MT; Dalle Carbonare L; Lo Cascio V
    J Bone Miner Res; 2010 Mar; 25(3):447-54. PubMed ID: 20200999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of intravenous and intramuscular neridronate regimens for the treatment of Paget disease of bone.
    Merlotti D; Rendina D; Gennari L; Mossetti G; Gianfrancesco F; Martini G; De Filippo G; Avanzati A; Franci B; Campagna MS; Strazzullo P; Nuti R
    J Bone Miner Res; 2011 Mar; 26(3):512-8. PubMed ID: 20814970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum 25 hydroxy-vitamin D does not exhibit an acute phase reaction after acute myocardial infarction.
    Barth JH; Field HP; Mather AN; Plein S
    Ann Clin Biochem; 2012 Jul; 49(Pt 4):399-401. PubMed ID: 22543926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of bisphosphonates for the treatment of osteonecrosis as a complication of therapy for childhood acute lymphoblastic leukaemia (ALL).
    Kotecha RS; Powers N; Lee SJ; Murray KJ; Carter T; Cole C
    Pediatr Blood Cancer; 2010 Jul; 54(7):934-40. PubMed ID: 20127847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Severe acute phase response after intravenous zoledronic acid in adult patients with cerebral palsy.
    Trinh A; Wong P; Ebeling PR; Fuller PJ; Milat F
    Intern Med J; 2016 Apr; 46(4):506-7. PubMed ID: 27062209
    [No Abstract]   [Full Text] [Related]  

  • 10. Gamma-delta T lymphocytes and 25-hydroxy vitamin D levels as key factors in autoimmunity and inflammation: the case of zoledronic acid-induced acute phase reaction.
    De Santis M; Cavaciocchi F; Ceribelli A; Crotti C; Generali E; Fabbriciani G; Selmi C; Massarotti M
    Lupus; 2015 Apr; 24(4-5):442-7. PubMed ID: 25801887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distribution and correlates of serum 25-hydroxyvitamin D levels in a sample of patients with hip fracture.
    Pieper CF; Colon-Emeric C; Caminis J; Betchyk K; Zhang J; Janning C; Shostak J; LeBoff MS; Heaney RR; Lyles KW
    Am J Geriatr Pharmacother; 2007 Dec; 5(4):335-40. PubMed ID: 18179991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute phase response following intravenous zoledronate in postmenopausal women with low bone mass.
    Anastasilakis AD; Polyzos SA; Makras P; Sakellariou GT; Bisbinas I; Gkiomisi A; Delaroudis S; Gerou S; Ballaouri I; Oikonomou D; Papapoulos SE
    Bone; 2012 May; 50(5):1130-4. PubMed ID: 22366634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term effects of intravenous pamidronate in fibrous dysplasia of bone.
    Chapurlat RD; Delmas PD; Liens D; Meunier PJ
    J Bone Miner Res; 1997 Oct; 12(10):1746-52. PubMed ID: 9333137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of serum 25-hydroxyvitamin D on the rate of pain episodes in Nigerian children with sickle cell anaemia.
    Adegoke SA; Oyelami OA; Adekile A; Figueiredo MS
    Paediatr Int Child Health; 2017 Aug; 37(3):217-221. PubMed ID: 28270033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of pamidronate in children with vitamin D intoxication.
    Kara C; Çetinkaya S; Gündüz S; Can Yılmaz G; Aycan Z; Aydın M
    Pediatr Int; 2016 Jul; 58(7):562-8. PubMed ID: 26646324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute phase response and mineral status following low dose intravenous zoledronic acid in children.
    Munns CF; Rajab MH; Hong J; Briody J; Högler W; McQuade M; Little DG; Cowell CT
    Bone; 2007 Sep; 41(3):366-70. PubMed ID: 17574945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of fibrous dysplasia of bone with intravenous pamidronate: long-term effectiveness and evaluation of predictors of response to treatment.
    Chapurlat RD; Hugueny P; Delmas PD; Meunier PJ
    Bone; 2004 Jul; 35(1):235-42. PubMed ID: 15207763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analytical Bias in the Measurement of Serum 25-Hydroxyvitamin D Concentrations Impairs Assessment of Vitamin D Status in Clinical and Research Settings.
    Black LJ; Anderson D; Clarke MW; Ponsonby AL; Lucas RM;
    PLoS One; 2015; 10(8):e0135478. PubMed ID: 26266807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Severe hypocalcemia after intravenous bisphosphonate therapy in occult vitamin D deficiency.
    Rosen CJ; Brown S
    N Engl J Med; 2003 Apr; 348(15):1503-4. PubMed ID: 12686715
    [No Abstract]   [Full Text] [Related]  

  • 20. The impact of vitamin D status on changes in bone mineral density during treatment with bisphosphonates and after discontinuation following long-term use in post-menopausal osteoporosis.
    Deane A; Constancio L; Fogelman I; Hampson G
    BMC Musculoskelet Disord; 2007 Jan; 8():3. PubMed ID: 17214897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.